Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BAL-1901
- Development stage
- Preclinical
- Lead developer
- BioAge Labs
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BAL-1901 is an investigational, orally active small molecule inhibitor of the NLRP3 (NACHT, LRR, and PYD domains-containing protein 3) inflammasome developed by BioAge Labs. It is designed to target chronic innate-immune injury and inflammation associated with aging and age-related diseases. In preclinical models, BAL-1901 has demonstrated protective effects on the retinal pigment epithelium (RPE) and retina in mouse models of geographic atrophy (GA) and dry age-related macular degeneration (AMD), significantly reducing lesion volume and preserving RPE junctional architecture. Additionally, BAL-1901 has been shown to reverse age-associated behavioral and inflammatory phenotypes in aged mice.
02
Targets
NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)
Beyond the preview
Go deeper on BAL-1901.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BAL-1901.